Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.05
Bid: 3.80
Ask: 4.30
Change: 0.15 (3.85%)
Spread: 0.50 (13.158%)
Open: 3.90
High: 4.05
Low: 3.72
Prev. Close: 3.90
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

Wed, 27th Mar 2024 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Norman Broadbent PLC, up 13% at 8.75 pence, 12-month range 4.50p-9.32p. The London-based recruitment firm swings to a pretax profit in 2023 of GBP309,000 from a loss of GBP338,000 in 2022. This tracks revenue rising 41% to GBP12.3 million from GBP8.7 million, partially offset by operating expenses rising 34%to GBP10.2 million from GBP7.6 million and cost of sales rising 21% to GBP1.7 million from GBP1.4 million. Chief Executive Officer Kevin Davidson comments: "We have taken the opportunity to invest further in the Company, hiring exceptional people and building our platform to take advantage of the market rebound when it comes. Our ambition remains steadfast and we will continue to pursue our aggressive growth strategy, whilst remaining profitable and cash positive, both organically and potentially through synergistic M&A opportunities...Supported by our considerable brand strength and market leading processes and technologies, we are well-positioned for continued success."

----------

Allergy Therapeutics PLC, up 11% at 3p, 12-month range 0.37p-3.20p. In the six months that ended December 31, the Sussex, England-based biotechnology company reports pretax loss widening to GBP14.9 million from GBP8.2 million a year earlier. Revenue falls 16% to GBP33.6 million from GBP39.9 million, while financial expenses soar to GBP3.2 million from GBP398,000. Chief Executive Officer Manuel Llobet comments: "2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy research & development programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth." Allergy Therapeutics also notes that its lenders have agreed that a further GBP15 million may be drawn from the existing GBP40 million amended loan facility from the second quarter of calendar 2024, with the first GBP7.5 million having already been drawn down. It says this extends its cash runway into the first quarter of its financial 2025. The lenders are major shareholders SkyGem Acquisition, which is an affiliate ZQ Capital Management, alongside Southern Fox Investments.

----------

AIM - LOSERS

----------

Infrastructure India PLC, down 80% at 0.10p, 12-month range 0.10p-1.27p. In the six months that ended September 30, the infrastructure fund investing directly into assets in India reports pretax loss narrowing to GBP31.5 million from GBP62.2 million a year earlier, largely driven by foreign exchange loss narrowing to GBP3.7 million from GBP40.8 million. Shares restarted trading on Wednesday after publishing its annual results for the financial year ended March 31 on Tuesday. During this period, pretax loss widened to GBP59.2 million from GBP48.4 million a year earlier. The company says: "The group has prepared the interim results on a basis other than going concern due to the uncertainty in relation to the timing of potential transactions, ultimate receipt of sale proceeds and the specifics of any deferred consideration. This basis was considered the most appropriate method for the reporting period."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
19 Sep 2014 15:09

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
19 Sep 2014 05:25

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
18 Sep 2014 15:23

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
18 Sep 2014 05:23

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
17 Sep 2014 15:01

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
17 Sep 2014 08:34

UK BROKER RATINGS: Berenberg Raises Johnson Matthey To Buy

Read more
17 Sep 2014 05:19

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
16 Sep 2014 15:11

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
16 Sep 2014 05:26

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Sep 2014 15:11

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
24 Jul 2014 11:37

Allergy Therapeutics Full Year Revenues To Beat Market Expectations

Read more
30 Apr 2014 10:18

Allergy Therapeutics Says Licence Renewed At Worthing Facility

LONDON (Alliance News) - Allergy Therapeutics PLC said that following the recent inspection of its facilities in Worthing by the Medicines and Healthcare Products Regulatory Agency, the firm Wednesday received its Certificate of GMP Compliance for the site. The specialty pharmaceutical firm

Read more
25 Apr 2014 08:44

DIRECTOR DEALINGS: Allergy Therapeutics Executives Acquire Shares

LONDON (Alliance News) - Allergy Therapeutics PLC said Friday that Chief Executive Manuel Llobet and Finance Director Ian Postlewaite acquired shares at nil cost under the company's long term share incentive plan on Thursday, as follows:

Read more
17 Apr 2014 10:44

Allergy Therapeutics Extends Term Of Convertible Loan

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it had extended the term of its GBP4.04 million convertible loan with CFR International SpA. The maturity of the loan has been extended to September 30 from April 20, all other terms of the loan are unchanged. Shares

Read more
1 Apr 2014 09:39

Tuesday broker round-up UPDATE

African Barrick Gold: Deutsche Bank raises target price from 240p to 310p and keeps a hold recommendation. African Minerals: Deutsche Bank lowers target price from 399p to 382p, while its buy recommendation is kept. Allergy Therapeutics: Panmure Gordon ups target price from 16p to 25p and retains

Read more

Quickpicks are a member only feature

Login to your account